Corvus Pharmaceuticals' (CRVS) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS - Free Report) in a research report report published on Monday morning, Benzinga reports.

Several other brokerages also recently weighed in on CRVS. Mizuho restated a neutral rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research note on Wednesday, March 27th. Oppenheimer reduced their price objective on shares of Corvus Pharmaceuticals from $8.00 to $7.00 and set an outperform rating on the stock in a research note on Wednesday, March 20th.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS stock traded up $0.08 on Monday, hitting $1.86. The stock had a trading volume of 117,243 shares, compared to its average volume of 217,097. The firm has a market capitalization of $91.21 million, a price-to-earnings ratio of -3.26 and a beta of 1.03. The stock's 50 day moving average is $2.08 and its 200-day moving average is $1.75. Corvus Pharmaceuticals has a 52-week low of $0.72 and a 52-week high of $4.19.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. Towerview LLC increased its stake in Corvus Pharmaceuticals by 27.6% during the 4th quarter. Towerview LLC now owns 436,873 shares of the company's stock valued at $769,000 after buying an additional 94,395 shares during the period. Vanguard Group Inc. boosted its position in shares of Corvus Pharmaceuticals by 3.5% during the 3rd quarter. Vanguard Group Inc. now owns 1,346,932 shares of the company's stock valued at $1,967,000 after purchasing an additional 45,707 shares in the last quarter. American Century Companies Inc. bought a new position in shares of Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000. Tucker Asset Management LLC bought a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $29,000. Finally, Goldman Sachs Group Inc. bought a new position in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $216,000. Institutional investors and hedge funds own 46.64% of the company's stock.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers.